You're not buying. Stocks like this normally do very well during times of greater market turmoil. Sometimes it's easier to invest in a potential blockbuster than to play the PE valuation game.
You'd think all these sellers would see they are running out of room to run. They have less than 6 months before first look in. Buyers are primed up. ATM was the only stahl for them. It's out now.
The bashers that post on here daily are not vested in anyway. So why are they here? What is the motive for bashing a developmental company that's trading in the one dollar range? Fiction becomes fact to these people in their pointless rants. Every one has owned a poor performing stock and usually moves on as a result of it. They don't consistently return to the MB's for that stock to bash it. Avid will be self sustaining soon. That alone will support the share price. If the FDA approves Bavi, then approves it again, and again and again, Bavi will be a combination therapy for almost all cancer types. If someone actually weighed the risk vs reward on that premise alone, they sure as hell wouldn't be short.
Somebody contributes relatively non-biased information to this board that is of mature context and look at the peanut gallery's responses below. For the short term, I think the shrinking cash position on the balance sheet and timeline required to complete the SUNRISE trial are going to be the biggest set back for the company. I agree that the safety aspects for the first look in will not impose any type of threat what so ever. I don't think there's a cancer treatment out there with a better safety profile to Bavituximab.
With MOS at almost 12 months, I wouldn't expect the development of any endpoints with current enrollees to be reached until late this year.
Opening strong doesn't seem to get it done in the afternoon/close. If you track the MACD for this stock, the swings can be easily identified. We're approaching another buying sequence. On the upside, the last buying frenzy expanded quite a bit. It will be interesting to see the next wave of positive momentum and what limits it will tolerate. We may be at the beginning of price expansion with SUNRISE results expected in 3rd or 4th quarter. We are already in the second quarter. The biggest question I have is: Is enrollment complete for the SUNRISE trial? If not, how many more patients are required to complete it? 11-12 months following the last patient enrollment will be the target period for the much anticipated announcement. Investors, long and short, have to remember these monoclonal antibodies are being used to treat/test TERMINAL cancer patients. Tumors that have grown and spread are difficult to kill with anything. Early detection and monoclonal antibodies offer a new era of hope...not a cure...but something that's one hell of a lot smarter and more effective than anything that's out there now.
So you are saying Bavi is getting approved? Cortara is a specific treatment for a specific type of cancer. Bavi is for all cancer types and does not require a complex delivery system. Almost non-existent toxicity as well. It won't ever make it to a shelf the demand will be so high.
I linked in through one of my previous alerts...anytime someone responds to your post you get a little alert. I can link in through my alerts only. Yahoo has shut down the message board link on the main page for Peregrine. No other stocks have the message board link shut down that I've researched. If it were for just a day or two, I'd assume it was being updated or there was a glitch. It appears to be an intentional action. Did you bother to investigate the non existent link? I've been following PPHM for a few years and frequently read MB posts. I've never seen this issue last for more than a day or two with any ticker and when it did occur it affected all tickers.
Highly suspicious activity going on. Desperate times call for desperate measures I guess. Big Pharma is scared. If monoclonal antibodies are the next generation of cancer treatment, how many product lines owned by Big Pharma are going to become obsolete? This is huge...Thomas Edison light bulb huge. It's the biggest threat the pharmaceutical industry has ever seen. Keeping Peregrines stock price depressed this low, it's pointless to partner with a company that could simply be bought outright. It's going to get interesting before the year is over.
Has anyone noticed Yahoo has shut down the "message board" link from Peregrine's page? It's been shut down for about a week now. I had to link into the message board through my alerts. All other tickers I pull up have the "message board" link available on the left where it's always been. When the bashing wasn't getting the job done on the this board, Big Pharma pulled out yet another stop throwing some cash at Yahoo to shut down the link? Coincidence has to stop at some point. A key employee passes away within months of the Sunrise results? I think Bavi is as big as peanut oil and the diesel engine. Oil companies weren't going to let someone market an engine that ran off peanut oil and the poor guy wound up dead. This thing is that big and foul play wouldn't surprise me.
They aren't short. They are paid bashers. Whether they actually know who's paying them or not, the big pharmaceutical companies want to keep this little gem depressed at all costs. No investor is going to spend that much time and effort posting on these boards unless they are being paid. Someone feels that keeping this stock down is of the highest priority and it's more than just a short tactic.
Did you see the free marketing from a few months ago from a newly approved inhalable insulin? If results of the phase 3 trial are inline with the phase 2 trial, every news network and radio station is going to be talking about it. If they can spool Avid up to meet Bavi's demand, a partner will not be necessary. This will be the only hurdle worth noting. I'm expecting a mass bidding war to occur between big Pharmaceutical companies for the acquisition of Peregrine the day the FDA approves Bavi for market. It could be as little as $6 to $9 a share or it could be $60 to $90 a share. Bavi is potentially the most versatile treatment application the pharmaceutical industry has ever seen. Breast and lung cancer trials have proven phenomenal so far. There are so many other possible ailments Bavi could address very effectively with minimal toxicity compared to anything that's out there now. When the FDA approves it, nobody and I mean nobody is going to care about the CEO's salary, share count, or other weaknesses within the company. This is a once in a lifetime opportunity for unheard of gains. Luckily the data mix up in phase 2 dropped this back down from $5. No placebo doubles MOS in a cancer patient. Take advantage of the stupidity of others.
and what will you do if they report growth over last year with additions of new wells? what's your plan if they've cut costs where ever they could have and report numbers in the black? PVA has potential to swing into the book value range once they go black.
Based on estimates for 2015...and assuming LUV can hit those estimates...@$50/sh LUV carries a PE of around 16...which is on the low/safe side. At this point in time an ultra safe buy easily extends up into the $60 range. One year targets will likely be upped into the $70-80 range which gives this current position plenty of breathing room. After earnings, LUV became overbought from a charting prospective. Even with the overbought condition, LUV managed to stay green the following day. This is a very good sign for short term pricing action for LUV.
You didn't answer the question. Why do you spend so much of your time bashing this stock? In other words what's in it for you?
DAL is up 7% on the day of it's earnings release. LUV has a couple days to make up ground off DAL positive results. I strongly believe LUV's earnings will be better than DAL's. The low fuel cost environment will bring investors for gains. The last quarter report didn't even begin to touch on what low fuel costs mean to the airline industry. The Q4 report will be a gentle taste test of low crude. Q1 will be the slam dunk quarter even though revenues tend to be weakest. If the Saudi's stick to it, this will be a record breaking year for the airline industry. $50/sh will be no sweat.
Dig into the history books brother. This is exactly how Beretta acquired their contract. Read up on how all the other "bidders" including S&W cried foul play when the military chose the latest model to hit the market. M&P was the last polymer line to hit the market and by golly all of a sudden one of the military branches want to change their sidearm...gee what a coincidence. Money matters and moving from an alloy framed sidearm to a polymer frame will reduce the overall project cost, but according to you the contract details are irrelevant. I agree with you...details are irrelevant because they have already made their choice, but they have to appear to accept all bids as if they mattered. Your username suggests you have worked for the government before, but you clearly have no idea how the government works. The torture tests were completed months ago on many different side arms based off of specific criteria assigned by the highest ranking officers. The Army is making it appear that competition exists within the government, but according to the Davis Bacon Act, it's guaranteed that it doesn't. History is repeating itself right now. Dig a little.
The military has already chosen which handgun they want. It's no surprise they denied Beretta. It's all about playing a pricing game right now. They want the M&P, but they will pretend to be interested in the other bids to create a better pricing platform for the contract. The exact same game was played with Beretta over 30 years ago. The Glock has been around for a long time and the military has never expressed interest in a possible switch until a few years after the M&P hits the market. M&P is the shoe in and it's all about contract details now.
I agree...not so much with Cramer but with the correlation between oil prices and earnings. Figure out which companies use the most fuel and those companies should have the best earnings. Hell if they were profitable at $110/barrel, they are over 3 times more profitable at $30/barrel. There is very good potential for those companies to make capital improvements with the extra cash for long term growth as well. The Saudi's are making this market right now and it's only logical to take all you can from it.